|
2022
|
Invention
|
Pulse dosing regimen and methods of treatment. A novel dosing regimen for erlotinib or a pharmace... |
|
2016
|
Invention
|
Pulse dosing regimen and methods for treatment. A novel dosing regimen for erlotinib or a pharmac... |
|
2015
|
Invention
|
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase ... |
|
2014
|
Invention
|
Processes for the preparation of isothiazole derivatives. Processes and intermediates for the pre... |
|
|
Invention
|
Regioselective synthesis of substituted pyrimidines. Disclosed are compounds of the Formula I:(I)... |
|
2013
|
Invention
|
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their forma... |
|
|
Invention
|
Preparation of c-pyrazine-methylamines.
A process for preparing a compound of formula (I) or a s... |
|
|
Invention
|
Fused bicyclic kinase inhibitors.
Compounds of Formula I, as shown below and defined herein:
C... |
|
|
Invention
|
Anti-cancer mtor inhibitor and anti-androgen combination. Methods and compositions for treating c... |
|
|
Invention
|
Combination anti-cancer therapy. The present invention provides a method for treating tumors or t... |
|
|
Invention
|
Biological markers predictive of anti-cancer response to kinase inhibitors.
The present inventio... |
|
|
Invention
|
Fused bicyclic mtor inhibitors. Compounds represented by Formula (I)
or a pharmaceutically acce... |
|
|
Invention
|
Amino pyrimidine anticancer compounds. Compounds of Formula 1, as shown below and defined herein:... |
|
|
Invention
|
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. Compounds of the formula
... |
|
2012
|
Invention
|
Proton nmr spectroscopy for biochemical screening. High-Throughput Screening (HTS) of large compo... |
|
|
Invention
|
Substituted pteridinones for the treatment of cancer. Compounds of Formula I, as shown below and ... |
|
|
Invention
|
Dihydropteridinones. Compounds of Formula I, as shown below and defined herein: pharmaceutically ... |
|
|
Invention
|
Fused bicyclic kinase inhibitors.
Compounds of Formula (I), pharmaceutically acceptable salts th... |
|
|
Invention
|
Fused bicyclic kinase inhibitors. Compounds of Formula (I), pharmaceutically acceptable salts the... |
|
|
Invention
|
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment. The present inve... |
|
|
Invention
|
Nsclc combination therapy. A method of treating NSCLC comprising in some aspects administering OS... |
|
|
Invention
|
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor ki... |
|
|
Invention
|
Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the ... |
|
2011
|
Invention
|
Macrocyclic kinase inhibitors. Compounds of Formula (I): wherein variables are defined herein, an... |
|
|
Invention
|
Process for the preparation of the compound osi - 906. Process for preparing the tyrosine kinase ... |
|
|
Invention
|
Polymorphs of osi-906. Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, p... |
|
|
Invention
|
Fused bicyclic kinase inhibitors.
Compounds of Formula I, as shown below and defined herein: pha... |
|
|
Invention
|
Fused bicyclic kinase inhibitors. Compounds of Formula I, as shown below and defined herein: (I) ... |
|
|
Invention
|
Fused bicyclic kinase inhibitors. Compounds of Formula I, as shown below and defined herein:
... |
|
|
Invention
|
Fused bicyclic kinase inhibitors. Compounds of Formula I, as shown below and defined herein: phar... |
|
|
Invention
|
Combination anti-cancer therapy.
Methods and compositions for treating cancer comprising adminis... |
|
|
Invention
|
Substituted-5-aminopyrrolo/pyrazolopyridines.
Compounds of Formula I, as shown below and defined... |
|
|
Invention
|
7-aminofuropyridine derivatives. Compounds of Formula 1, as shown below and defined herein:
phar... |
|
|
Invention
|
Pet imaging.
A method for determining whether to administer a therapeutically effective amount o... |
|
2010
|
Invention
|
Deuterated tyrosine kinase inhibitors.
Compounds of Formula I, as shown below and defined herein... |
|
|
Invention
|
Mtor inhibitor and angiogenesis inhibitor combination therapy.
Cancer therapy comprising treatme... |
|
|
Invention
|
C-pyrazine-methylamines. A process for preparing a compound of formula (I) or a salt thereof: (I)... |
|
|
Invention
|
Combination anti-cancer therapy.
The present invention provides a method for treating tumors or ... |
